Tag
pfizer
2 articles
Pfizer's Dividend Is Safe—And Cheap at 6.2% Yield
CEO Bourla and CFO Guegan made unambiguous commitments to maintaining and growing the dividend despite patent cliff risks, while the company's acquisition-driven growth portfolio is outpacing expectations.
Pfizer's 17.5% Return on Capital Justifies Premium; Sherwin-Williams and Cisco Face Valuation Risk
Pfizer's industry-leading capital returns and fixed-cost leverage support its 9.8x forward P/E, while Sherwin-Williams at 27.1x and Cisco at 21.9x trade at multiples that don't justify their slowing growth and declining efficiency.